Exchange: NASDAQ·Updated 07:30 PM EST

KZIA News

News
all
press releases
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026 Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026PR NewswireSYDNEY, Nov. 19, 2026 SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics...
PR Newswire
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026 Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026PR NewswireSYDNEY, Nov. 19, 2026 SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics...
PR Newswire
More News
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein...
PR Newswire
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough AwardsPR NewswireSYDNEY, Nov. 5, 2026 Recognition Highlights Kazia's Focus on Overcoming...
PR Newswire
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster...
PR Newswire
Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).read more...
Benzinga
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation ConferencePR NewswireSYDNEY, Oct. 29, 2026 SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia...
PR Newswire
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersPR NewswireSYDNEY, Sept. 22, 2026 Clinical Milestone...
PR Newswire
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer PR Newswire SYDNEY...
PR Newswire
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances...
PR Newswire
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing...
PR Newswire

Advertisement|Remove ads.